Bolt Biotherapeutics (FRA:6LP) Short-Term Capital Lease Obligation : €2.78 Mil (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Bolt Biotherapeutics Short-Term Capital Lease Obligation?

Bolt Biotherapeutics's Short-Term Capital Lease Obligation for the quarter that ended in Jun. 2024 was €2.78 Mil.

Bolt Biotherapeutics's quarterly Short-Term Capital Lease Obligation increased from Dec. 2023 (€2.55 Mil) to Mar. 2024 (€2.66 Mil) and increased from Mar. 2024 (€2.66 Mil) to Jun. 2024 (€2.78 Mil).

Bolt Biotherapeutics's annual Short-Term Capital Lease Obligation increased from Dec. 2021 (€2.21 Mil) to Dec. 2022 (€2.26 Mil) and increased from Dec. 2022 (€2.26 Mil) to Dec. 2023 (€2.55 Mil).

Bolt Biotherapeutics Short-Term Capital Lease Obligation Historical Data

The historical data trend for Bolt Biotherapeutics's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bolt Biotherapeutics Short-Term Capital Lease Obligation Chart

Bolt Biotherapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

2.79

1.23

2.21

2.26

2.55

Bolt Biotherapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															2.38	2.51	2.55	2.66	2.78

Bolt Biotherapeutics Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Bolt Biotherapeutics Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Bolt Biotherapeutics's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Bolt Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bolt Biotherapeutics Inc (FRA:6LP) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

BOLT:USA 6LP:Germany

Address

900 Chesapeake Drive, Redwood, CA, USA, 94063

Website

https://www.boltbio.com

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

Bolt Biotherapeutics Headlines

No Headlines